spec sheet7 rows
Acetergamine is an ergoline (ergot alkaloid) derivative studied for alpha-1 adrenergic receptor-blocking and vasodilator activity. It was never developed into a marketed drug.
- Covered in patents exploring erectile dysfunction treatment, based on its vasodilator and alpha-1 blocking activity
- Also investigated as a potential treatment for cerebellar ataxia
Overview
An ergot-family compound that surfaces mostly in old erectile-dysfunction and cerebellar-ataxia patents rather than in any real drug pipeline.
Mechanism
Acetergamine antagonizes alpha-1 receptors and promotes (blood vessel relaxation). As a member of the ergoline class, it shares a chemical backbone with ergot-derived agonists, though its own dopaminergic activity, if any, is not well characterized in available sources.
receptor fingerprint
Alpha-1 receptorAntagonist
Safetyrisks and cautions, not medical advice
Acetergamine was never tested in significant human clinical trials and has no established safety profile. As with other ergoline derivatives, general ergot-class concerns (such as vasospasm or fibrotic reactions with chronic ergot exposure) are a theoretical class consideration, though none have been specifically documented for this compound due to the lack of clinical testing.
Subjective profileweighing the evidence above
Nothing here to act on. It never reached clinical trials, so the erectile dysfunction and ataxia ideas are patent claims rather than findings, and the ergoline backbone carries class concerns nobody has ruled out for it. Of historical interest only.
Resources
This entry is here for reference.
Reviews
My notesprivate to this device
FAQ
What is Acetergamine used for?
It has no approved use. It appears in patents related to erectile dysfunction and cerebellar ataxia based on its vasodilator and alpha-1 adrenergic blocking activity, but it was never marketed.
How does Acetergamine work?
It blocks alpha-1 adrenergic receptors, which relaxes blood vessels (vasodilation). It belongs to the ergoline chemical class, related to ergot-derived dopamine agonists.
Is Acetergamine well-researched?
No. Documentation is limited mostly to patent literature and basic chemical classification, with no meaningful clinical trial record.
Limitations of the evidence
- Never reached clinical trials or marketing; no human safety data exists
- General ergoline-class risks are a theoretical concern but have not been specifically studied for this compound